Abstract:Background Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment. The effectiveness of radiation and chemotherapy remains uncertain owing to conflicting results in previous reports. Questions/purposes To review our experience with contemporary multimodality treatment, we asked: (1) What is the disease-specific survival and local relapse-free survival? (2) Does American Joint Commission on Cancer (AJCC) stage, tumor size, or location relate to disease outcome? (3) Does radiation therapy improve local control or survival? (4) Do doxorubicin and ifosfamide improve local control or survival? Methods Between 1990 and 2012, we treated 40 patients for localized, high-grade extraosseous osteosarcoma. In this retrospective study, we could determine the status of 36 patients (90%) either to death or for a minimum of 24 months of followup; four (10%) were lost to followup before 24 months. There were 11 patients with AJCC Stage IIA and 25 with Stage III disease. All patients underwent wide surgical excision. Of the patients with Stage IIA disease, four received radiation and none received chemotherapy. Of the patients with Stage III disease, six received radiation, seven were treated with chemotherapy, and six received radiation and chemotherapy. During the study period, high-dose doxorubicin and ifosfamide was the preferred chemotherapy regimen for patients younger than 60 years with normal cardiac and renal function. Local relapse-free survival and disease-specific survival were determined by Kaplan-Meier analysis using a prospectively maintained institutional database supplemented by information from the institutional tumor registry. The Cox proportional hazard model was used to determine the effect of various factors on local recurrence and patient survival. Results At 5 years, local relapse-free survival was 47% (95% CI, 27%-64%), and disease-specific survival was 53% (95% CI, 35%-68%). In multivariate analysis, AJCC stage, which depends on tumor size, was the strongest predictor of local relapse-free survival (hazard ratio [HR] = 0.17, p = 0.02), while tumor depth was the best predictor of disease-specific survival (HR = 5.6, p = 0.02). Radiation improved local relapse-free survival (HR = 0.30, p = 0.03) but not disease-specific survival in multivariate analysis. A regimen of doxorubicin and ifosfamide was associated with better local relapse-free survival for patients with Stage III disease (HR = 0.16, p = 0.04) but not disease-specific survival (HR = 0.32, p = 0.08). Conclusions With the limited number of patients in our study, it appears that extraosseous osteosarcoma behaves differently than osteosarcoma of bone. Multimodality treatment that includes doxorubicin and ifosfamide-based chemotherapy, radiation, and surgery may be a valid therapeutic strategy for Stage III disease, but larger, prospective studies will be needed to verify our preliminary observations. Level of Evidence Level III, therapeutic study.

Role of Chemotherapy in Treatment of Osteosarcoma

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

The Treatment of Stage III Osteosarcoma

[Evaluation of Neoadjuvant Chemotherapy for Patients with Stage II Osteosarcoma].

Treatment of Extremity Osteosarcoma with Neoadjuvant Chemotherapy and Limb Salvage

[Long-term results of combined therapy for primary osteosarcoma in extremities of 189 cases]

Neoadjuvant chemotherapy combined with limb salvage surgery for treatment of osteosarcoma long - term survival analysis

Survival Analysis of 311 Patients with Osteosarcoma of the Extremities Treated in a Single Institute

The Role of Chemotherapy in the Survival Benefits of Patients Aged Older Than 40 Years With Osteosarcoma

Surgical Resection of Osteosarcoma at the Metaphysis with Joint Preservation

Clinical Study on the New Adjuvant Chemotherapy for the Treatment of Osteosarcoma

Outcome of Patients with Osteosarcoma after Recurrence and Analysis of Factors Affecting the Long-Term Survival——a Long-Term Follow-Up Study of Recurrent Patients by Multicenter

A Multi-Center Retrospective Analysis of Clinical Prognosis in Children with Extremity Osteosarcoma

Progress in the Chemotherapeutic Treatment of Osteosarcoma (Review)

The Survival of Patients with Osteosarcoma Influenced by Chemotherapy Induced Tumor Necrosis and Tumor Volume Variation, the Chinese Experience

Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.

Should High-grade Extraosseous Osteosarcoma Be Treated with Multimodality Therapy Like Other Soft Tissue Sarcomas?

A Retrospective Clinical Study of the Efficacy of Chemotherapy Combined with Adjuvant Radiation Therapy in the Treatment of AJCC Stage II or Stage III Soft Tissue Sarcoma of the Extremity after Wide Excision

Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta‐Analysis

[Prognostic Factors for 72 Patients with Osteosarcoma of the Extremity Treated with Neoadjuvant Chemotherapy].

Clinical therapeutic efficacy analysis of the optimized neo-adjuvant chemotherapy protocols in the treatment of osteosarcoma